Masao Matsuoka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2621263/publications.pdf

Version: 2024-02-01

299	16,151	11651 70	20961 115
papers	citations	h-index	g-index

314	314	314	10924
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevention of acute graft-versus-host disease in adult T-cell leukemiaâ€“lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation. International Journal of Hematology, 2022, 115, 435-439.	1.6	3
2	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	1.4	44
3	HTLV-1's Foxy Strategy for Survival and Transmission. Frontiers in Virology, 2022, 1, .	1.4	2
4	A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells. Biochemical and Biophysical Research Communications, 2022, 587, 153-159.	2.1	9
5	Predictive impact of soluble interleukinâ€2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large Bâ€cell lymphoma. EJHaem, 2022, 3, 385-393.	1.0	1
6	HTLV-1 activates YAP via NF-ÎºB/p65 to promote oncogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	10
7	Targeting vulnerabilities of adult T-cell leukemia. Blood, 2022, 139, 1435-1435.	1.4	0
8	Blocking cholesterol efflux mechanism is a potential target for antilymphoma therapy. Cancer Science, 2022, , .	3.9	6
9	Functional and Pathogenic Roles of Retroviral Antisense Transcripts. Frontiers in Immunology, 2022, 13, 875211.	4.8	6
10	Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma. British Journal of Haematology, 2022, 198, .	2.5	2
11	Beneficial impact of firstâ€line mogamulizumabâ€containing chemotherapy in adult Tâ€cell leukaemiaâ€lymphoma. British Journal of Haematology, 2022, 198, 983-987.	2.5	10
12	A regulatory element in the 3â€²â€untranslated region of CEBPA is associated with myeloid/NK/Tâ€cell leukemia. European Journal of Haematology, 2021, 106, 327-339.	2.2	5
13	The noncanonical role of EZH2 in cancer. Cancer Science, 2021, 112, 1376-1382.	3.9	40
14	In vivo dynamics and adaptation of HTLV-1-infected clones under different clinical conditions. PLoS Pathogens, 2021, 17, e1009271.	4.7	9
15	Genome wide association study of HTLV-1â€“associated myelopathy/tropical spastic paraparesis in the Japanese population. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
16	Adult Tâ€cell leukemiaâ€lymphoma as a viral disease: Subtypes based on viral aspects. Cancer Science, 2021, 112, 1688-1694.	3.9	18
17	The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2027-2030.	2.4	0
18	Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	23

#	Article	IF	Citations
19	Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 370-387.	5.0	19
20	Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases. Molecular Cancer, 2021, 20, 86.	19.2	7
21	A case of primary nonleukemic myeloid sarcoma of the spleen, successfully treated by surgery and hematopoietic stem cell transplantation. Surgical Case Reports, 2021, 7, 180.	0.6	0
22	A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid. Antimicrobial Agents and Chemotherapy, 2021, 65, e0103921.	3.2	11
23	Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. Cancers, 2021, 13, 5674.	3.7	1
24	M-Sec induced by HTLV-1 mediates an efficient viral transmission. PLoS Pathogens, 2021, 17, e1010126.	4.7	4
25	HTLV-1 bZIP factor: the key viral gene for pathogenesis. Retrovirology, 2020, 17, 2.	2.0	65
26	HTLV-1 induces T cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 13740-13749.	7.1	31
27	Hematopoietic stem cells acquire survival advantage by loss of RUNX1 methylation identified in familial leukemia. Blood, 2020, 136, 1919-1932.	1.4	20
28	IL-2/IL-2 Receptor Pathway Plays a Crucial Role in the Growth and Malignant Transformation of HTLV-1-Infected T Cells to Develop Adult T-Cell Leukemia. Frontiers in Microbiology, 2020, 11, 356.	3.5	12
29	Frequent horizontal and mother-to-child transmission may contribute to high prevalence of STLV-1 infection in Japanese macaques. Retrovirology, 2020, 17, 15.	2.0	5
30	A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor. Journal of Virology, 2020, 94, .	3.4	7
31	IL-7Râ€“Dependent Phosphatidylinositol 3-Kinase Competes with the STAT5 Signal to Modulate T Cell Development and Homeostasis. Journal of Immunology, 2020, 204, 844-857.	0.8	9
32	Systematic clustering algorithm for chromatin accessibility data and its application to hematopoietic cells. PLoS Computational Biology, 2020, 16, e1008422.	3.2	2
33	Oncofetal Protein SALL4 Is Highly Expressed in Myelodysplastic Syndrome Alongside with NAT10 and P53. Blood, 2020, 136, 34-34.	1.4	0
34	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	1.4	0
35	Title is missing!. , 2020, 16, e1008422.		0
36	Title is missing!. , 2020, 16, e1008422.		0

#	Article	IF	Citations
37	Title is missing!. , 2020, 16, e1008422.		0
38	Title is missing!. , 2020, 16, e1008422.		0
39	Title is missing!. , 2020, 16, e1008422.		0
40	Title is missing!. , 2020, 16, e1008422.		0
41	Title is missing!. , 2020, 16, e1008422.		0
42	Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 338-342.	2.4	13
43	Expression of <scp>IL</scp>â€34 correlates with macrophage infiltration and prognosis of diffuse large Bâ€cell lymphoma. Clinical and Translational Immunology, 2019, 8, e1074.	3.8	13
44	Regulation of Latency in the Human T Cell Leukemia Virus, HTLV-1. Annual Review of Virology, 2019, 6, 365-385.	6.7	27
45	Clinical potential of dual-energy cardiac CT in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 91-92.	3.0	1
46	Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors. Biochemistry and Biophysics Reports, 2019, 20, 100687.	1.3	3
47	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. Journal of Clinical Oncology, 2019, 37, 677-687.	1.6	162
48	Pentosan Polysulfate Demonstrates Anti-human T-Cell Leukemia Virus Type 1 ActivitiesIn VitroandIn Vivo. Journal of Virology, 2019, 93, .	3.4	8
49	40 years of the human T-cell leukemia virus: past, present, and future. F1000Research, 2019, 8, 228.	1.6	60
50	<scp>TUBB</scp>1 dysfunction in inherited thrombocytopenia causes genome instability. British Journal of Haematology, 2019, 185, 888-902.	2.5	14
51	HTLV-1 Dysregulates IL-6 and IL-10-JAK/STAT Signaling and Induces Leukemia/Lymphoma of Mature CD4+ T Cells with Regulatory T-Cell-like Signatures. Blood, 2019, 134, 1516-1516.	1.4	1
52	Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation. Blood, 2019, 134, 1810-1810.	1.4	1
53	Mogamulizumab (Anti-CCR4) in HTLV-1â€“Associated Myelopathy. New England Journal of Medicine, 2018, 378, 529-538.	27.0	79
54	Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1269-E1278.	7.1	135

#	Article	IF	Citations
55	Oncogenic spiral by infectious pathogens: Cooperation of multiple factors in cancer development. Cancer Science, 2018, 109, 24-32.	3.9	31
56	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	1.4	124
57	Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin Gene. Internal Medicine, 2018, 57, 1905-1910.	0.7	6
58	Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/<i>RUNX1-RUNX1T1</i> Rearrangement. Internal Medicine, 2018, 57, 563-568.	0.7	9
59	Distinct gene expression signatures induced by viral transactivators of different HTLV-1 subgroups that confer a different risk of HAM/TSP. Retrovirology, 2018, 15, 72.	2.0	16
60	The Roles of Coinhibitory Receptors in Pathogenesis of Human Retroviral Infections. Frontiers in Immunology, 2018, 9, 2755.	4.8	11
61	Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2018, 58, 152-160.	0.8	17
62	Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2. Journal of Virology, 2018, 92, .	3.4	24
63	CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases. Journal of the American Academy of Dermatology, 2018, 79, 1039-1046.	1.2	20
64	Evaluating the origin and virulence of a Helicobacter pylori cagA-positive strain isolated from a non-human primate. Scientific Reports, 2018, 8, 15981.	3.3	11
65	HTLV-1 Alters T Cells for Viral Persistence and Transmission. Frontiers in Microbiology, 2018, 9, 461.	3.5	25
66	ASSESSMENT OF POOR MOBILIZATION USING PERIPHERAL BLOOD STEM CELLS BY AN AUTOMATED HEMATOLOGY ANALYZER. Japanese Journal of Transfusion and Cell Therapy, 2018, 64, 510-515.	0.2	2
67	HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. Scientific Reports, 2017, 7, 12849.	3.3	13
68	Human T-cell leukaemia virus type 1: parasitism and pathogenesis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2017, 372, 20160272.	4.0	65
69	Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Research, 2017, 137, 41-48.	4.1	116
70	Circadian clock regulates hepatic polyploidy by modulating Mkp1-Erk1/2 signaling pathway. Nature Communications, 2017, 8, 2238.	12.8	28
71	Cell adhesion molecule-1 (CADM1) expressed on adult T-cell leukemia/lymphoma cells is not involved in the interaction with macrophages.. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 15-20.	0.8	6
72	Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 21-25.	0.8	25

#	Article	IF	Citations
73	II. Leukemogenesis and Mechanisms of HTLV-1 Replication and Infection. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1376-1382.	0.0	0
74	HTLV-1 bZIP Factor Enhances T-Cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathogens, 2017, 13, e1006120.	4.7	46
75	Human T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo. PLoS Pathogens, 2017, 13, e1006722.	4.7	56
76	An ILâ€27/Stat3 axis induces expression of programmed cell death 1 ligands (<scp>PD</scp>â€L1/2) on infiltrating macrophages in lymphoma. Cancer Science, 2016, 107, 1696-1704.	3.9	104
77	Gpr176 is a Gz-linked orphan G-protein-coupled receptor that sets the pace of circadian behaviour. Nature Communications, 2016, 7, 10583.	12.8	60
78	Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody. Scientific Reports, 2016, 6, 27150.	3.3	17
79	Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology, 2016, 13, 70.	2.0	10
80	TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma. Oncology Letters, 2016, 12, 1519-1524.	1.8	17
81	HTLV-1 Viral Factor HBZ Induces CCR4 to Promote T-cell Migration and Proliferation. Cancer Research, 2016, 76, 5068-5079.	0.9	60
82	Multifaceted functions and roles of HBZ in HTLV-1 pathogenesis. Retrovirology, 2016, 13, 16.	2.0	110
83	HTLV-1 bZIP factor protein targets the Rb/E2F-1 pathway to promote proliferation and apoptosis of primary CD4+ T cells. Oncogene, 2016, 35, 4509-4517.	5.9	32
84	HTLV-1 subgroups associated with the risk of HAM/TSP are related to viral and host gene expression in peripheral blood mononuclear cells, independent of the transactivation functions of the viral factors. Journal of NeuroVirology, 2016, 22, 416-430.	2.1	20
85	HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT). PLoS Pathogens, 2016, 12, e1005372.	4.7	67
86	Impact of the SCF signaling pathway on leukemia stem cell-mediated ATL initiation and progression in an HBZ transgenic mouse model. Oncotarget, 2016, 7, 51027-51043.	1.8	5
87	Human <scp>T</scp>â€cell leukemia virus type 1 <scp>T</scp>ax oncoprotein represses the expression of the <scp>BCL</scp>11<scp>B</scp> tumor suppressor in <scp>T</scp>â€cells. Cancer Science, 2015, 106, 461-465.	3.9	15
88	Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood, 2015, 126, 1095-1105.	1.4	62
89	Experimental evaluation of the zoonotic infection potency of simian retrovirus type 4 using humanized mouse model. Scientific Reports, 2015, 5, 14040.	3.3	5
90	Interferon-Î³ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice. PLoS Pathogens, 2015, 11, e1005120.	4.7	31

#	Article	IF	Citations
91	Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds. Organic and Biomolecular Chemistry, 2015, 13, 4706-4713.	2.8	14
92	Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold. Bioorganic and Medicinal Chemistry, 2015, 23, 1447-1452.	3.0	19
93	Reevaluation of confirmatory tests for human <scp>T</scp>â€cell leukemia virus <scp>T</scp>ype 1 using a luciferase immunoprecipitation system in blood donors. Transfusion, 2015, 55, 880-889.	1.6	9
94	Clinical outcomes of a novel therapeutic vaccine with Tax peptideâ€pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. British Journal of Haematology, 2015, 169, 356-367.	2.5	101
95	TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2216-2221.	7.1	25
96	Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread. Virology, 2015, 484, 364-376.	2.4	9
97	Involvement of double-stranded RNA-dependent protein kinase and antisense viral RNA in the constitutive NFÎºB activation in adult T-cell leukemia/lymphoma cells. Leukemia, 2015, 29, 1425-1429.	7.2	7
98	Integrated molecular analysis of adult T cell leukemia/lymphoma. Nature Genetics, 2015, 47, 1304-1315.	21.4	659
99	HTLV-1 bZIP Factor RNA and Protein Impart Distinct Functions on T-cell Proliferation and Survival. Cancer Research, 2015, 75, 4143-4152.	0.9	75
100	HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP. Virology Journal, 2014, 11, 172.	3.4	16
101	A Critical Role for IL-17RB Signaling in HTLV-1 Tax-Induced NF-ÎºB Activation and T-Cell Transformation. PLoS Pathogens, 2014, 10, e1004418.	4.7	25
102	Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. International Immunology, 2014, 26, 419-425.	4.0	16
103	The structure and genomic integration site of the HTLV-1 provirus determine selective clonal expansion and transformation to adult T cell leukaemia/lymphoma. Retrovirology, 2014, 11, .	2.0	1
104	Integration site analysis in Japanese HTLV-1 infected asymptomatic carriers and HAM/TSP patients. Retrovirology, 2014, 11, .	2.0	1
105	STLV-1-infected Japanese macaque as a model of HTLV-1 infection. Retrovirology, 2014, 11, O12.	2.0	2
106	The phase-I study of a therapeutic vaccine to ATL patients with autologous dendritic cells pulsed with peptides corresponding to Tax-specific CTL epitopes. Retrovirology, 2014, 11, .	2.0	1
107	HTLV-1-mediated dysregulation of the Wnt pathways: roles of Tax and HBZ. Retrovirology, 2014, 11, P91.	2.0	2
108	Epsteinâ€“Barr Viral Load is Associated to Response in AIDS-Related Lymphomas. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 191-4.	0.6	3

#	Article	IF	Citations
109	HTLV-1 bZIP Factor Suppresses Apoptosis by Attenuating the Function of FoxO3a and Altering Its Localization. Cancer Research, 2014, 74, 188-200.	0.9	62
110	Controlling leucine-zipper partner recognition in cells through modification of aâ€“g interactions. Chemical Communications, 2014, 50, 6364-6367.	4.1	8
111	Development of T cell lymphoma in HTLV-1 bZIP factor and Tax double transgenic mice. Archives of Virology, 2014, 159, 1849-1856.	2.1	27
112	The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma. Blood, 2014, 123, 3925-3931.	1.4	112
113	Human T-Cell Leukemia Virus Type 1: Pathogenesis and Host Immune Response. , 2014, , 229-262.		0
114	Structureâ€“activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4557-4561.	2.2	22
115	Design and synthesis of biotin- or alkyne-conjugated photoaffinity probes for studying the target molecules of PD 404182. Bioorganic and Medicinal Chemistry, 2013, 21, 2079-2087.	3.0	14
116	HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPÎ± signaling. Retrovirology, 2013, 10, 159.	2.0	20
117	Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Current Opinion in Virology, 2013, 3, 684-691.	5.4	89
118	Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. International Journal of Biochemistry and Cell Biology, 2013, 45, 908-915.	2.8	6
119	Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection. Retrovirology, 2013, 10, 118.	2.0	36
120	Virological and immunological mechanisms in the pathogenesis of human Tâ€cell leukemia virus type 1. Reviews in Medical Virology, 2013, 23, 269-280.	8.3	17
121	HTLV-1 bZIP Factor Induces Inflammation through Labile Foxp3 Expression. PLoS Pathogens, 2013, 9, e1003630.	4.7	74
122	HIV-1 Vpr Accelerates Viral Replication during Acute Infection by Exploitation of Proliferating CD4+ T Cells In Vivo. PLoS Pathogens, 2013, 9, e1003812.	4.7	49
123	HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. Antimicrobial Agents and Chemotherapy, 2013, 57, 4035-4038.	3.2	6
124	ComprehensiveIn VitroAnalysis of Simian Retrovirus Type 4 Susceptibility to Antiretroviral Agents. Journal of Virology, 2013, 87, 4322-4329.	3.4	6
125	HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells. Oncogene, 2013, 32, 4222-4230.	5.9	65
126	Molecular and Cellular Mechanism of Leukemogenesis of ATL: Emergent Evidence of a Significant Role for HBZ in HTLV-1-Induced Pathogenesis. Leukemia Research and Treatment, 2012, 2012, 1-8.	2.0	17

#	Article	IF	Citations
127	Human T-Cell Leukemia Virus Type 1 (HTLV-1) bZIP Factor Requires Cellular Transcription Factor JunD To Upregulate HTLV-1 Antisense Transcription from the 3â€² Long Terminal Repeat. Journal of Virology, 2012, 86, 9070-9078.	3.4	52
128	Development and application of fluorescent SDF-1 derivatives. Future Medicinal Chemistry, 2012, 4, 837-844.	2.3	4
129	HTLV-2 APH-2 Expression Is Correlated With Proviral Load but APH-2 Does Not Promote Lymphocytosis. Journal of Infectious Diseases, 2012, 205, 82-86.	4.0	37
130	HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines. Blood, 2012, 119, 434-444.	1.4	64
131	CXCR4 Stimulates Macropinocytosis: Implications for Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV. Chemistry and Biology, 2012, 19, 1437-1446.	6.0	103
132	A simple, rapid, and sensitive system for the evaluation of anti-viral drugs in rats. Biochemical and Biophysical Research Communications, 2012, 424, 257-261.	2.1	9
133	HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+T cells in virus-infected individuals. Retrovirology, 2012, 9, 46.	2.0	85
134	Structureâ€“activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents. Bioorganic and Medicinal Chemistry, 2012, 20, 6434-6441.	3.0	25
135	Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles. Organic and Biomolecular Chemistry, 2012, 10, 6792.	2.8	24
136	HBZ and its roles in HTLV-1 oncogenesis. Frontiers in Microbiology, 2012, 3, 247.	3.5	68
137	FOXP3⁺ regulatory and TIAâ€1⁺ cytotoxic T lymphocytes in HIVâ€associated Hodgkin lymphoma. Pathology International, 2012, 62, 77-83.	1.3	11
138	Potent CXCR4 Antagonists Containing Amidine Type Peptide Bond Isosteres. ACS Medicinal Chemistry Letters, 2011, 2, 477-480.	2.8	33
139	A novel animal model of Epstein-Barr virusâ€“associated hemophagocytic lymphohistiocytosis in humanized mice. Blood, 2011, 117, 5663-5673.	1.4	96
140	HTLV-1 bZIP factor enhances TGF-Î² signaling through p300 coactivator. Blood, 2011, 118, 1865-1876.	1.4	119
141	Detection of HTLVâ€1 by means of HBZ gene in situ hybridization in formalinâ€fixed and paraffinâ€embedded tissues. Cancer Science, 2011, 102, 1432-1436.	3.9	15
142	Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene, 2011, 30, 1379-1389.	5.9	232
143	Molecular mechanisms of HTLV-1 infection and pathogenesis. International Journal of Hematology, 2011, 94, 435-442.	1.6	80
144	Guest editorial: a new era of ATL and HTLV-1 research. International Journal of Hematology, 2011, 94, 429-429.	1.6	0

#	Article	IF	Citations
145	ATF3, an HTLV-1 bZip factor binding protein, promotes proliferation of adult T-cell leukemia cells. Retrovirology, 2011, 8, 19.	2.0	73
146	Potent Anti-HIV-1 Activity of N-HR-Derived Peptides Including a Deep Pocket-Forming Region without Antagonistic Effects on T-20. Antiviral Chemistry and Chemotherapy, 2011, 22, 51-55.	0.6	3
147	HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation In Vivo. PLoS Pathogens, 2011, 7, e1001274.	4.7	267
148	Maximizing Functional Photoreceptor Differentiation From Adult Human Retinal Stem Cells. Stem Cells, 2010, 28, 489-500.	3.2	70
149	Revisiting Human IL-12RÎ²1 Deficiency. Medicine (United States), 2010, 89, 381-402.	1.0	367
150	Binding of Multivalent Anionic Porphyrins to V3 Loop Fragments of an HIVâ€1 Envelope and Their Antiviral Activity. Chemistry - an Asian Journal, 2010, 5, 825-834.	3.3	11
151	Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. Antiviral Research, 2010, 87, 179-186.	4.1	17
152	HTLV-1 and the Host Immune System : How the Virus Disrupts Immune Regulation, Leading to HTLV-1 Associated Diseases. Journal of Clinical and Experimental Hematopathology: JCEH, 2010, 50, 1-8.	0.8	35
153	Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors. Journal of Biological Chemistry, 2010, 285, 39471-39480.	3.4	37
154	APOBEC3G Generates Nonsense Mutations in Human T-Cell Leukemia Virus Type 1 Proviral Genomes In Vivo. Journal of Virology, 2010, 84, 7278-7287.	3.4	106
155	HTLV-1 bZIP factor gene: Its roles in HTLV-1 pathogenesis. Molecular Aspects of Medicine, 2010, 31, 359-366.	6.4	26
156	Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4. International Journal of Biochemistry and Cell Biology, 2010, 42, 1482-1488.	2.8	6
157	Synthesis and biological evaluation of selective CXCR4 antagonists containing alkene dipeptide isosteres. Organic and Biomolecular Chemistry, 2010, 8, 616-621.	2.8	71
158	Multi-Step Aberrant CpG Island Hyper-Methylation Is Associated with the Progression of Adult Tâ€“Cell Leukemia/Lymphoma. American Journal of Pathology, 2010, 176, 402-415.	3.8	68
159	Affinity selection and sequence-activity relationships of HIV-1 membrane fusion inhibitors directed at the drug-resistant variants. MedChemComm, 2010, 1, 276.	3.4	3
160	SC29EK, a Peptide Fusion Inhibitor with Enhanced Î±-Helicity, Inhibits Replication of Human Immunodeficiency Virus Type 1 Mutants Resistant to Enfuvirtide. Antimicrobial Agents and Chemotherapy, 2009, 53, 1013-1018.	3.2	82
161	SKI and MEL1 Cooperate to Inhibit Transforming Growth Factor-Î² Signal in Gastric Cancer Cells. Journal of Biological Chemistry, 2009, 284, 3334-3344.	3.4	74
162	Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*. Journal of Biological Chemistry, 2009, 284, 4914-4920.	3.4	41

#	Article	IF	Citations
163	Mechanism of Inhibition of HIV-1 Reverse Transcriptase by 4â€²-Ethynyl-2-fluoro-2â€²-deoxyadenosine Triphosphate, a Translocation-defective Reverse Transcriptase Inhibitor. Journal of Biological Chemistry, 2009, 284, 35681-35691.	3.4	117
164	HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes. Journal of General Virology, 2009, 90, 1806-1811.	2.9	63
165	Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. Antiviral Research, 2009, 82, 67-72.	4.1	25
166	Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naÃ¯ve patients. Antiviral Research, 2009, 82, 115-121.	4.1	38
167	Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group. Bioorganic and Medicinal Chemistry, 2009, 17, 7964-7970.	3.0	11
168	Design and synthesis of membrane fusion inhibitors against the feline immunodeficiency virus. Bioorganic and Medicinal Chemistry, 2009, 17, 4916-4920.	3.0	5
169	Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins. Bioorganic and Medicinal Chemistry, 2009, 17, 7487-7492.	3.0	8
170	Electrostatically constrained Î±-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. International Journal of Biochemistry and Cell Biology, 2009, 41, 891-899.	2.8	59
171	X-ray Crystallographic Study of an HIV-1 Fusion Inhibitor with the gp41 S138A Substitution. Journal of Molecular Biology, 2009, 392, 657-665.	4.2	15
172	DNA double strand break repair enzymes function at multiple steps in retroviral infection. Retrovirology, 2009, 6, 114.	2.0	35
173	In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). Retrovirology, 2009, 6, 19.	2.0	150
174	The HBZ gene, a key player in HTLV-1 pathogenesis. Retrovirology, 2009, 6, 71.	2.0	136
175	Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-ÎºB. Blood, 2009, 113, 2755-2764.	1.4	164
176	Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of Î±-helical anti-HIV peptide analogues. Organic and Biomolecular Chemistry, 2009, 7, 2872.	2.8	105
177	Development of a Novel Fusion Inhibitor against T-20-resistant HIV-1. Advances in Experimental Medicine and Biology, 2009, 611, 389-391.	1.6	1
178	Synthesis and Application of Fluoresceinâ€•and Biotinâ€Łabeled Molecular Probes for the Chemokine Receptor CXCR4. ChemBioChem, 2008, 9, 1154-1158.	2.6	39
179	Identification of minimal sequence for HIV-1 fusion inhibitors. Bioorganic and Medicinal Chemistry, 2008, 16, 9184-9187.	3.0	25
180	Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4124-4129.	2.2	29

#	Article	IF	Citations
181	Novel screening systems for HIV-1 fusion mediated by two extra-virion heptad repeats of gp41. Antiviral Research, 2008, 80, 71-76.	4.1	8
182	2â€²-Deoxy-4â€²-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. International Journal of Biochemistry and Cell Biology, 2008, 40, 2410-2420.	2.8	114
183	Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia/Lymphoma: Impact of Antithymocyte Globulin on Clinical Outcome. Biology of Blood and Marrow Transplantation, 2008, 14, 702-708.	2.0	56
184	A Potential Link between Alternative Splicing of theNBS1Gene and DNA Damage/Environmental Stress. Radiation Research, 2008, 170, 33-40.	1.5	5
185	Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity. Journal of Medicinal Chemistry, 2008, 51, 388-391.	6.4	55
186	Transcriptional Control of Spliced and Unspliced Human T-Cell Leukemia Virus Type 1 bZIP Factor () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.4	115
187	Dual-Reporter Phenotypic Assay for Human Immunodeficiency Viruses. Journal of Clinical Microbiology, 2008, 46, 792-795.	3.9	4
188	Binding Modes of Two Novel Non-Nucleoside Reverse Transcriptase Inhibitors, YM-215389 and YM-228855, to HIV Type-1 Reverse Transcriptase. Antiviral Chemistry and Chemotherapy, 2008, 19, 133-141.	0.6	2
189	Heptad Repeat-Derived Peptides Block Protease-Mediated Direct Entry from the Cell Surface of Severe Acute Respiratory Syndrome Coronavirus but Not Entry via the Endosomal Pathway. Journal of Virology, 2008, 82, 588-592.	3.4	42
190	Roles for MicroRNAs, miR-93 and miR-130b, and Tumor Protein 53â€“Induced Nuclear Protein 1 Tumor Suppressor in Cell Growth Dysregulation by Human T-Cell Lymphotrophic Virus 1. Cancer Research, 2008, 68, 8976-8985.	0.9	172
191	Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors. Journal of Virology, 2008, 82, 3261-3270.	3.4	88
192	Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). Journal of Virology, 2008, 82, 764-774.	3.4	330
193	Phenotypic and Genotypic Comparisons of Human T-Cell Leukemia Virus Type 1 Reverse Transcriptases from Infected T-Cell Lines and Patient Samples. Journal of Virology, 2007, 81, 4422-4428.	3.4	18
194	2â€²-Deoxy-4â€²-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 1543-1546.	1.1	49
195	Cooperation of NF-ÎºB2/p100 Activation and the PDZ Domain Binding Motif Signal in Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax1 but Not HTLV-2 Tax2 Is Crucial for Interleukin-2-Independent Growth Transformation of a T-Cell Line. Journal of Virology, 2007, 81, 11900-11907.	3.4	93
196	Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4â€²-Ethynyl-2-Fluoro-2â€²-Deoxyadenosine. Antimicrobial Agents and Chemotherapy, 2007, 51, 2701-2708.	3.2	96
197	Preferential Selection of Human T-Cell Leukemia Virus Type 1 Provirus Lacking the 5â€² Long Terminal Repeat during Oncogenesis. Journal of Virology, 2007, 81, 5714-5723.	3.4	102
198	Human T-Cell Leukemia Virus Type I Induces Adult T-Cell Leukemia: From Clinical Aspects to Molecular Mechanisms. Cancer Control, 2007, 14, 133-140.	1.8	71

#	Article	IF	Citations
199	Leukaemogenic mechanism of human Tâ€¢cell leukaemia virus type I. Reviews in Medical Virology, 2007, 17, 301-311.	8.3	35
200	Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nature Reviews Cancer, 2007, 7, 270-280.	28.4	726
201	Development of adult T-cell leukemia in donor-derived human T-cell leukemia virus type I-infected T cells after allogeneic bone marrow transplantation. Leukemia, 2007, 21, 1594-1596.	7.2	8
202	GANP suppresses DNA recombination, measured by direct-repeat ?-galactosidase gene construct, but does not suppress the type of recombination applying to immunoglobulin genes in mammalian cells. Genes To Cells, 2007, 12, 1205-1213.	1.2	19
203	Implication of the HTLV-I bZIP Factor Gene in the Leukemogenesis of Adult T-Cell Leukemia. International Journal of Hematology, 2007, 86, 107-112.	1.6	15
204	Establishment of Novel Disease Models for Human Acute Type ATL and HTLV-I Carrier Using NOD-scid/IL2rgnull Mouse.. Blood, 2007, 110, 2797-2797.	1.4	0
205	Novel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics. Journal of Medicinal Chemistry, 2006, 49, 1506-1508.	6.4	311
206	Sea Urchin Arylsulfatase Insulator Exerts its Anti-silencing Effect without Interacting with the Nuclear Matrix. Journal of Molecular Biology, 2006, 357, 18-27.	4.2	5
207	Human T-Cell Leukemia Virus Type I. , 2006, , 464-475.		3
208	Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene, 2006, 25, 2181-2191.	5.9	56
209	Chromosomal abnormalities in non-hodgkin lymphoma with peripheral t-cell type: Effect of HTLV-I infection. Hematological Oncology, 2006, 5, 157-166.	1.7	9
210	Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation. New England Journal of Medicine, 2006, 354, 1758-1759.	27.0	60
211	Ars Insulator Identified in Sea Urchin Possesses an Activity to Ensure the Transgene Expression in Mouse Cells. Journal of Biochemistry, 2006, 139, 705-714.	1.7	12
212	2â€²-Deoxy-4â€²-C-ethynyl-2-fluoroadenosine: A nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma. Nucleic Acids Symposium Series, 2006, 50, 1-2.	0.3	18
213	A Novel Colorimetric Assay for CXCR4 and CCR5 Tropic Human Immunodeficiency Viruses. Antiviral Chemistry and Chemotherapy, 2006, 17, 215-223.	0.6	9
214	De Novo Human T-Cell Leukemia Virus Type 1 Infection of Human Lymphocytes in NOD-SCID, Common Î³-Chain Knockout Mice. Journal of Virology, 2006, 80, 10683-10691.	3.4	49
215	HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 720-725.	7.1	546
216	Structural Basis for the Interaction of CCR5 with a Small Molecule, Functionally Selective CCR5 Agonist. Journal of Immunology, 2006, 177, 3116-3122.	0.8	31

#	Article	IF	Citations
217	Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood, 2005, 106, 1048-1053.	1.4	64
218	Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structureâ€“activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 949-961.	3.0	24
219	Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene, 2005, 24, 6047-6057.	5.9	199
220	RNase S complex bearing arginine-rich peptide and anti-HIV activity. Journal of Molecular Recognition, 2005, 18, 169-174.	2.1	7
221	Mutations Conferring Resistance to Human Immunodeficiency Virus Type 1 Fusion Inhibitors Are Restricted by gp41 and Rev-Responsive Element Functions. Journal of Virology, 2005, 79, 764-770.	3.4	87
222	Human T-Cell Leukemia Virus Type I at Age 25: A Progress Report: Figure 1.. Cancer Research, 2005, 65, 4467-4470.	0.9	40
223	Halogenated Thymidine Analogues Restore the Expression of Silenced Genes without Demethylation. Cancer Research, 2005, 65, 6927-6933.	0.9	15
224	Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology, 2005, 2, 27.	2.0	127
225	Silencing of human T-cell leukemia virus type I gene transcription by epigenetic mechanisms. Retrovirology, 2005, 2, 64.	2.0	163
226	Methylation Profile of B-Chronic Lymphocytic Leukemia Cells.. Blood, 2005, 106, 2951-2951.	1.4	0
227	Attempt to Reduce Cytotoxicity by Synthesizing the L-Enantiomer of 4â€²-C-Ethynyl-2â€²-Deoxypurine Nucleosides as Antiviral Agents against HIV and HBV. Antiviral Chemistry and Chemotherapy, 2004, 15, 161-167.	0.6	3
228	Identification of Aberrantly Methylated Genes in Association with Adult T-Cell Leukemia. Cancer Research, 2004, 64, 6002-6009.	0.9	123
229	Sea urchin insulator protects lentiviral vector from silencing by maintaining active chromatin structure. Gene Therapy, 2004, 11, 819-828.	4.5	48
230	Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia, 2004, 18, 1357-1363.	7.2	122
231	Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naÃ¯ve patients. Virology, 2004, 327, 215-224.	2.4	16
232	Genetic and epigenetic inactivation oftax gene in adult T-cell leukemia cells. International Journal of Cancer, 2004, 109, 559-567.	5.1	309
233	Role of HTLVâ€1 proviral DNA load and clonality in the development of adult Tâ€cell leukemia/lymphoma in asymptomatic carriers. International Journal of Cancer, 2004, 110, 621-625.	5.1	98
234	Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. Bioorganic and Medicinal Chemistry, 2004, 12, 6171-6182.	3.0	16

#	Article	IF	Citations
235	Design, Efficient Synthesis, and Antiâ€HIV Activity of 4â€²â€Câ€Cyanoâ€and 4â€²â€Câ€Ethynylâ€2â€²â€deoxy Purine Nucleosides. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 671-690.	1.1	44
236	Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood, 2004, 103, 2753-2760.	1.4	91
237	Aberrantly Hypermethylated Genes in Adult T-Cell Leukemia Cells: The Implications in the Leukemogenesis.. Blood, 2004, 104, 3493-3493.	1.4	0
238	Leukemogenesis of Adult T-Cell Leukemia. International Journal of Hematology, 2003, 78, 312-320.	1.6	17
239	Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma. International Journal of Hematology, 2003, 77, 512-517.	1.6	44
240	Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene, 2003, 22, 5131-5140.	5.9	181
241	Influence of cytokine and mannose binding protein gene polymorphisms on human t-cell leukemia virus type i (hTLV-i) provirus load in HTLV-I asymptomatic carriers. Human Immunology, 2003, 64, 453-457.	2.4	17
242	Synthesis of 4â€²-C-Ethynyl and 4â€²-C-Cyano Purine Nucleosides from Natural Nucleosides and Their Anti-HIV Activity. Nucleosides, Nucleotides and Nucleic Acids, 2003, 22, 887-889.	1.1	4
243	Genetic Evidence of Transmission of Human T Cell Lymphotropic Virus Type 1 between Spouses. Journal of Infectious Diseases, 2002, 185, 691-695.	4.0	36
244	Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor ÎºB ligand on adult T-cell leukemia cells. Blood, 2002, 99, 634-640.	1.4	162
245	Association between interleukin-6 gene polymorphism and human T-Cell leukemia virus type I associated myelopathy. Human Immunology, 2002, 63, 696-700.	2.4	25
246	Remodeling of gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 with Target Cells We thank Dr. Terrence R. Burke, Jr., NCI, NIH, Frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Japan Society for the Promotion of Science, and the Japan Health Science Foundation.. Angewandte Chemie - International Edition, 2002, 41, 2937.	13.8	157
247	Central nervous system lesions in adult T-cell leukaemia: MRI and pathology. Neuroradiology, 2002, 44, 559-567.	2.2	34
248	Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4+25+ HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis. Oncogene, 2002, 21, 2466-2475.	5.9	79
249	Impaired production of naive T lymphocytes in human T-cell leukemia virus type Iâ€“infected individuals: its implications in the immunodeficient state. Blood, 2001, 97, 3177-3183.	1.4	134
250	Missense mutation of the interleukin-12 receptor Î²1 chainâ€“encoding gene is associated with impaired immunity againstMycobacterium avium complex infection. Blood, 2001, 97, 2688-2694.	1.4	83
251	Synthetic peptide-based electrochemiluminescence immunoassay for anti-Borna disease virus p40 and p24 antibodies in rat and horse serum. Annals of Clinical Biochemistry, 2001, 38, 348-355.	1.6	18
252	Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1897-1902.	2.2	115

#	Article	IF	Citations
253	Sequential Change of Virus Markers in Seroconverters with Communityâ€Acquired Infection of Human T Lymphotropic Virus Type I. Journal of Infectious Diseases, 2001, 183, 1031-1037.	4.0	21
254	4â€²-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro. Antimicrobial Agents and Chemotherapy, 2001, 45, 1539-1546.	3.2	137
255	Syntheses of 4â€˜-C-Ethynyl-Î²-d-arabino- and 4â€˜-C-Ethynyl-2â€˜-deoxy-Î²-d-ribo-pentofuranosylpyrimidines and -purines and Evaluation of Their Anti-HIV Activity. Journal of Medicinal Chemistry, 2000, 43, 4516-4525.	6.4	84
256	Identification of Human Autoantibodies to the Transcriptional Repressor ZF5. Journal of Autoimmunity, 2000, 15, 75-80.	6.5	8
257	Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-Î±, and HLA-DRB1 gene polymorphisms in human T-Cell lymphotropic virus type I associated myelopathy. Human Immunology, 2000, 61, 1262-1269.	2.4	26
258	The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41. FEBS Letters, 2000, 487, 185-188.	2.8	15
259	Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Research, 2000, 60, 1043-8.	0.9	99
260	Polymorphism of the 5â€²â€Flanking Region of the Tumor Necrosis Factor (TNF)â€“Î± Gene and Susceptibility to Human Tâ€Cell Lymphotropic Virus Type I (HTLVâ€I) Uveitis. Journal of Infectious Diseases, 1999, 180, 880-883.	4.0	36
261	Rapid quantification of HTLV-I provirus load: Detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. , 1999, 81, 859-864.		50
262	Provirus Load in Patients with Human T-Cell Leukemia Virus Type 1 Uveitis Correlates with Precedent Graves' Disease and Disease Activities. Japanese Journal of Cancer Research, 1998, 89, 608-614.	1.7	45
263	Interferon-Î±-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages. Oncogene, 1998, 16, 2075-2086.	5.9	53
264	Random integration of HTLV-I provirus; increasing chromosomal instability. Cancer Letters, 1998, 132, 203-212.	7.2	25
265	Mutation of CD95 (Fas/Apo-1) Gene in Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3935-3942.	1.4	129
266	Mutation of CD95 (Fas/Apo-1) Gene in Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3935-3942.	1.4	8
267	Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood, 1998, 91, 3935-42.	1.4	36
268	Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13897-13902.	7.1	268
269	Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Research, 1997, 57, 4862-7.	0.9	142
270	DNA Diagnosis of HTLV-I. Intervirology, 1996, 39, 158-164.	2.8	4

#	Article	IF	Citations
271	Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood, 1996, 88, 3065-3073.	1.4	220
272	Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood, 1996, 88, 3065-73.	1.4	110
273	Constitutive overexpression of the L-selectin gene in fresh leukemic cells of adult T-cell leukemia that can be transactivated by human T- cell lymphotropic virus type 1 Tax. Blood, 1995, 86, 3109-3117.	1.4	48
274	The 3â€² enhancer region determines the B/T specificity and pro-B/pre-B specificity of immunoglobulin VÎº-JÎº joining. Cell, 1995, 83, 1113-1123.	28.9	60
275	Constitutive overexpression of the L-selectin gene in fresh leukemic cells of adult T-cell leukemia that can be transactivated by human T- cell lymphotropic virus type 1 Tax. Blood, 1995, 86, 3109-3117.	1.4	3
276	A novel diagnostic method of adult T-cell leukemia: monoclonal integration of human T-cell lymphotropic virus type I provirus DNA detected by inverse polymerase chain reaction. Blood, 1994, 84, 3080-3085.	1.4	105
277	Deregulated c-fos Modulates B Cell Responses to Switch Mediators. Cellular Immunology, 1993, 149, 82-90.	3.0	6
278	Analysis of the Expression of Seven G Protein Î± Subunit Genes in Hematopoietic Cells. American Journal of the Medical Sciences, 1993, 306, 89-93.	1.1	7
279	Immunoglobulin V gene replacement is caused by the intramolecular DNA deletion mechanism.. EMBO Journal, 1992, 11, 611-618.	7.8	31
280	Immunoglobulin V gene replacement is caused by the intramolecular DNA deletion mechanism. EMBO Journal, 1992, 11, 611-8.	7.8	12
281	The Development of Sleep and Wakefulness Cycle in Early Infancy and Its Relationship to Feeding Habit.. Tohoku Journal of Experimental Medicine, 1991, 165, 147-154.	1.2	9
282	Immunoglobulin switch circular DNA in the mouse infected with Nippostrongylus brasiliensis: evidence for successive class switching from mu to epsilon via gamma 1.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7829-7833.	7.1	109
283	Switch circular DNA formed in cytokine-treated mouse splenocytes: Evidence for intramolecular DNA deletion in immunoglobulin class switching. Cell, 1990, 62, 135-142.	28.9	237
284	Characterization of the human gene for Gx alpha, a pertussis toxin-insensitive regulatory GTP-binding protein. Journal of Biological Chemistry, 1990, 265, 13215-20.	3.4	31
285	A B-CELL LINE HAVING CHROMOSOME 14 ABERRATION AT BREAK BAND q11 DERIVED FROM AN ADULT T-CELL LEUKEMIA PATIENT. Japanese Journal of Cancer Research, 1988, 79, 12-16.	1.7	3
286	Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory protein alpha subunit.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 5384-5388.	7.1	206
287	Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood, 1988, 71, 1021-1026.	1.4	81
288	Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood, 1988, 71, 1021-1026.	1.4	31

#	Article	IF	Citations
289	T Cell Î³ Chain Gene Rearrangement without T Cell Receptor Î² Chain Gene Rearrangement in Two Cases of Non-Hodgkinâ€™s Lymphoma. Acta Haematologica, 1987, 77, 172-176.	1.4	5
290	Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood, 1987, 70, 1407-1411.	1.4	76
291	Expression of the HT462 antigen on fresh leukemic T cells and on cells of HTLV-I infected lines. Leukemia Research, 1987, 11, 251-257.	0.8	0
292	Interleukin 1 gene expression in adult T cell leukemia.. Journal of Clinical Investigation, 1987, 80, 911-916.	8.2	149
293	T3 surface molecules on adult T cell leukemia cells are modulated in vivo. Blood, 1986, 67, 1070-1076.	1.4	47
294	Expression of tac antigen on human immature B-cell lineage leukemic cells. Leukemia Research, 1986, 10, 597-603.	0.8	15
295	Analysis of anti-HTLV-I antibody by strip radioimmunoassayâ€”comparison with indirect immunofluorescence assay, enzyme-linked immunosorbent assay and membrane immunofluorescence assay. Leukemia Research, 1986, 10, 605-610.	0.8	6
296	T3 surface molecules on adult T cell leukemia cells are modulated in vivo. Blood, 1986, 67, 1070-6.	1.4	11
297	Natural antibodies in sera from Japanese individuals infected with HTLV- I do not recognize HTLV-III. Blood, 1985, 66, 745-747.	1.4	9
298	HTLV-III Infection and Epitope Recognition by OKT4 Monoclonal Antibody. New England Journal of Medicine, 1985, 313, 1543-1544.	27.0	3
299	Adult T-Cell Leukemia/Lymphoma. , 0, , 211-229.		3